AzTrials
AzTrials

Systemic Lupus ErythematosusPRIMULA_PregNCT06659029

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

An observational study of Systemic Lupus Erythematosus, run by AstraZeneca at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. Read more about this study

Who is it for?
Any age, women only
Conditions the study is for
Systemic Lupus Erythematosus
What is being tested?
Anifrolumab
Type of treatment
Injection or infusion
How many people
442 participants
Where
1 siteUnited States
Study dates
1 Jul 2025to 15 Apr 2031
How long will I take part?
21 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: The study population will include 2 cohorts of pregnant individuals: a cohort of individuals with moderate/severe SLE who are exposed to anifrolumab and a cohort of individuals with moderate/severe SLE who are unexposed to anifrolumab but who are exposed to other products for the treatment of SLE.

Who may be able to join

  • Exposed cohort
  • Currently or recently (within 1 year of pregnancy outcome) pregnant
  • Diagnosis of moderate/severe SLE
  • Consent to participate
  • Authorization for their HCP(s) to provide data to the registry
  • Exposure to at least 1 dose of anifrolumab at any time during pregnancy
Show all 12Show fewer
  • Unexposed cohort
  • Currently or recently pregnant
  • Diagnosis of moderate/severe SLE
  • Consent to participate
  • Authorization for their HCP(s) to provide data to the registry
  • Exposure to other products for the treatment of moderate/severe SLE

Who cannot join

  • Exposed cohort
  • Occurrence of pregnancy outcome prior to first contact (for enrollment) with the Virtual Research Coordination Center (retrospectively enrolled)
  • Exposure to known teratogens and/or investigational medications during pregnancy
  • Unexposed cohort
  • Occurrence of pregnancy outcome prior to first contact with the Virtual Research Coordination Center (retrospectively enrolled)
  • Exposure to known teratogens and/or investigational medications during pregnancy

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

United States1 site, 1 recruiting
  • Research Site

    Wilmington, North Carolina, 28401

    Recruiting

Other trials in United States

About this study

Official title: PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users): The AstraZeneca Pregnancy Study for Anifrolumab

PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study will fulfil an FDA post-marketing requirement.

Read the detailed description

PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a US-based, prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. The objective of the pregnancy registry is to compare adverse maternal, fetal, and infant outcomes of pregnant individuals with moderate/severe systemic lupus erythematosus (SLE) who are exposed to anifrolumab during pregnancy with outcomes in an internal comparison cohort of pregnant individuals with moderate/severe SLE who are not exposed to anifrolumab during pregnancy. Participation in the registry is voluntary and participants can withdraw their consent to participate at any time. The study is strictly observational; the schedule of office visits and all treatment regimens will be determined by HCPs. Only data that are documented in patients' medical records during medical care will be actively collected. No additional laboratory tests or HCP assessments will be required as part of this registry. This study will fulfil an FDA post-marketing requirement.

Being tested
Anifrolumab
Keywords
Chronic autoimmune disease, Immunosuppressants, Corticosteroids, Human monoclonal antibody (IgG1ƙ mAb), Post Marketing Requirements (PMR) study, Pregnancy, Systemic Lupus Erythematosus
Medical subject headings
Lupus Erythematosus, Systemic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AnifrolumabDrug

    Also called Saphnelo

    Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.

Study groups in NCT06659029
Study groupRoleWhat they receive
Exposed cohortPregnant individuals with a diagnosis of moderate/severe SLE who are exposed to anifrolumab at any time during pregnancy
Receives: Drug: Anifrolumab
Unexposed cohortPregnant individuals with a diagnosis of moderate/severe SLE who are not exposed to anifrolumab at any time during pregnancy but who are exposed to other products for the treatment of SLE

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Composite outcome of all major congenital malformations (MCMs)

    An abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention. Relevant exposure window is limited to 1st trimester of pregnancy.

    Measured: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births

Secondary outcomes (15)
  1. Composite outcome of all minor congenital malformations

    An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e., birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual. Relevant exposure window includes any trimester of pregnancy.

    Measured: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births

  2. Worsening of underlying disease

    Any increase in disease activity or severity in the pregnancy period compared to the baseline period (6 months prior to pregnancy) as assessed by the disease flare or disease activity algorithms or as reported by an HCP. Relevant exposure window includes any trimester of pregnancy.

    Measured: From date of conception (DOC) to pregnancy outcome, up to 42 weeks of pregnancy

  3. Premature rupture of membranes

    A disorder of pregnancy defined as rupture of membranes before the onset of labor. Relevant exposure window includes any trimester of pregnancy.

    Measured: From date of conception (DOC) to pregnancy outcome, up to 42 weeks of pregnancy

  4. Pregnancy-induced hypertension

    A disorder of pregnancy defined as a systolic blood pressure 140 mmHg or more or a diastolic blood pressure of 90 mmHg or more, or both, on 2 occasions at least 4 hours apart after 20 weeks gestation, in a woman with a previously normal blood pressure. Relevant exposure window includes any trimester of pregnancy.

    Measured: From 20 gestational weeks to pregnancy outcome, up to 42 weeks of pregnancy

  5. Composite outcome of preeclampsia/eclampsia

    Preeclampsia is a disorder of pregnancy associated with new-onset hypertension, which occurs most often after 20 weeks of gestation and frequently near term, and proteinuria. Or, in the absence of proteinuria, it is defined as new-onset hypertension with the new onset of any of the following:

    • Thrombocytopenia: platelet count less <100 ,000/mL
    • Renal insufficiency: serum creatinine concentrations >1.1mg/dL or a doubling of the serum creatinine concentration in the absence of other renal disease
    • Impaired liver function: elevated blood concentrations of liver transaminases to twice normal concentration
    • Pulmonary edema
    • New-onset headache unresponsive to medication and not accounted for by alternative diagnoses or visual symptoms.

    Eclampsia is new-onset tonic-clonic, focal, or multifocal seizures in the absence of other causative conditions such as epilepsy, cerebral arterial ischemia and infarction, intracranial hemorrhage, or drug use.

    Measured: From 20 gestational weeks to pregnancy outcome, up to 42 weeks of pregnancy

  6. Maternal hospitalization for serious illness

    An inpatient hospital admission unrelated to delivery occurring during pregnancy. Relevant exposure window includes any trimester of pregnancy.

    Measured: From date of conception (DOC) to pregnancy outcome, up to 42 weeks of pregnancy

  7. Spontaneous abortion

    An involuntary fetal loss or the expulsion of the products of conception occurring at <20 gestational weeks.

    Measured: From date of conception (DOC) to <20 gestational weeks

  8. Elective termination

    An intervention that is intended to terminate a suspected or known ongoing intrauterine pregnancy and that does not result in a live birth. Relevant exposure window includes any trimester of pregnancy.

    Measured: From date of conception (DOC) to pregnancy outcome, up to 24 weeks of pregnancy

  9. Emergency caesarean section

    A cesarean delivery that is performed due an immediate threat to the health or safety of the fetus and/or the mother. Relevant exposure window includes any trimester of pregnancy.

    Measured: From date of conception (DOC) to pregnancy outcome, up to 42 weeks of pregnancy

  10. Preterm birth

    A live birth occurring at <37 gestational weeks.

    Measured: From date of conception (DOC) up to 37 gestational weeks

  11. Small for gestational age

    Birthweight <10th percentile for sex and gestational age using standard growth charts for full and preterm live-born infants. Relevant exposure window includes any trimester of pregnancy.

    Measured: At delivery of live birth

  12. Postnatal growth deficiency

    Weight, length, or head circumference in <10th percentile for sex and chronological age using standard growth charts. Relevant exposure window includes any trimester of pregnancy.

    Measured: At 4 and 12 months of infant age

  13. Infant developmental delay

    Failure to achieve the developmental milestones for chronological age, as defined by the CDC. Relevant exposure window includes any trimester of pregnancy.

    Measured: At 4 and 12 months of infant age

  14. Infant hospitalization for serious illness

    An inpatient hospital admission occurring in the first year of life. Relevant exposure window includes any trimester of pregnancy.

    Measured: From birth to 1 year of infant age

  15. Infant serious or opportunistic infection

    An infection that occurs within an infant's first year of life and is either opportunistic (i.e., occurs more often or is more severe in people with weakened immune systems than in people with healthy immune systems) or serious (i.e., results in significant disability, incapacity, or death; is life-threatening; requires inpatient or prolonged hospitalization; or is considered medically important). Relevant exposure window includes any trimester of pregnancy.

    Measured: From birth to 1 year of infant age

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Oct 2024
  2. Study start1 Jul 2025
  3. Primary completion15 Apr 2031 (estimated)
  4. Study completion15 Apr 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
442 participants (estimated)
Target duration
21 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT06659029
Sponsor's protocol ID
D3461R00051
Acronym
PRIMULA_Preg
Status last verified
Aug 2026
First submitted
14 Oct 2024
Last updated
2 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of Companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ will accept requests for IPD, but this does not mean all requests will be approved.

Questions about this trial

What is this clinical trial studying?

An observational study of Systemic Lupus Erythematosus, run by AstraZeneca at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Composite outcome of all major congenital malformations (MCMs) (time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in